How to Set Up a Chain of Pharmacies on Under £200k: Buy the Contract, Not the Shop

Here’s a question I got asked: how are people buying one pharmacy, putting down a big deposit, and ending up with an independent chain so quickly? It’s a brilliant question — and the honest answer is a piece of financial plumbing most people have never heard of: invoice discounting. You buy the first shop the hard way, with real money down. After that, you stop funding deposits out of your own pocket and start funding them out of your guaranteed NHS income. That’s the trick. And it only works because what you’re really acquiring isn’t bricks, fittings and stock — it’s NHS contracts: stable, government-backed, bankable income streams. Buy the contract, not the shop.

This is the written companion to my video answering that exact question. If you’d rather hear the trick from me first, watch it here, then read on for the detail.

The trick: invoice discounting

Let’s answer the question head-on. Say you buy your first pharmacy — a decent one, worth around £1 million. You have to put a deposit down. Even if you’re lucky enough to find a lender who’ll fund 80% of the goodwill, you’re still finding roughly 20% yourself; on a more typical 30% deposit it’s more again. Either way, call it about £200,000 of your own money into shop number one. So the obvious question — the one I was asked — is this: where does the deposit for shop number two come from? If you’re not cash-rich, or sitting on assets you can flip, you need another lever. That lever is invoice discounting.

Here’s how it works. Your NHS payment statement is guaranteed, regular income — say you’re banking around £100,000 every month, like clockwork, from the NHS. An invoice-discounting firm will advance you cash against that guaranteed income before it lands. Take two months’ worth — £200,000 of income — and they might pay you roughly £160,000 of it now, up front. They keep a drawdown or hold-back and charge a set percentage for the service. There are terms and conditions and they matter — I’m flagging them rather than pretending they don’t exist — but the mechanism itself is simple: guaranteed NHS income turned into cash today instead of in two months’ time.

Now you’ve got roughly £160,000 sitting in your account, and that becomes the deposit for your next pharmacy. Here’s why it compounds: shop number two has its own turnover and its own regular NHS income — so you do exactly the same thing again, and then again. It’s the property playbook applied to pharmacies: buy one, build it up, pull the value back out, use it to fund the next, repeat. That’s how someone with £200k of real equity ends up controlling an independent chain far faster than the sticker prices suggest. Invoice discounting is simply the sharpest expression of this article’s whole spine — the NHS contract is the bankable asset.

Be clear-eyed about it, though. Every time you pull this lever you’re taking on more interest and more debt, and the guaranteed NHS income that makes the whole thing lendable is exactly what you’re mortgaging to do it. It’s an idea, not a guarantee — have a proper think before you lean on it. Leverage cuts both ways, a theme that runs through everything below.

Why one shop costs £500k — and why that’s the wrong number

Let’s deal with the sticker price first, because it’s what stops most people before they start. A genuinely decent community pharmacy in 2026 sells for somewhere north of £500,000, and good ones run well into seven figures. I’ve written the honest version of those numbers in should you buy a community pharmacy in 2026 and in opening vs buying a pharmacy. Look at that headline figure and a chain feels absurd: four shops, £2 million, come back when you’ve sold a kidney.

But that £500k is the price of buying a shop outright — paying the full enterprise value in cash or fully-drawn debt, taking the keys, and owning the lot on day one. That is one way to acquire a pharmacy. It is not the only way, and for someone assembling a group on modest capital it’s the worst way, because it consumes your entire war chest on a single asset. The reframe that changes everything: you are not trying to own shops. You are trying to control contracts. And a contract can be controlled with a fraction of its value in your own money.

The whole strategy in one idea: the contract is the asset

Strip a pharmacy back to what actually makes it valuable and you’re left with one thing: the right to dispense NHS prescriptions from that location and be paid for it, month after month, by the NHS. That’s the NHS pharmaceutical contract — and it is a genuinely unusual asset. The income is regular. It’s backed by the government, not by a fickle customer base. And it’s scarce, because you can’t simply open a new pharmacy wherever you fancy — market entry is controlled, which I explain in why you can’t just open a pharmacy.

That combination — regular, protected, scarce income — is exactly what a lender loves and exactly what makes a pharmacy financeable. It’s also why a pharmacy that is losing money can still command a six-figure price. The buyer isn’t paying for last year’s loss; they’re paying for the contract and what a competent operator can do with it. Deals genuinely happen where a pharmacy haemorrhaging around £100,000 a year still sells for £200,000-plus — purely for the contract — because a new owner who runs it lean and bolts private services on top can flip it to profit. Once you internalise that, the shop itself becomes almost incidental. Buy contracts, and you buy income streams. Buy shops, and you buy overheads.

But do pharmacies even make money?

This whole strategy rests on one assumption: that the contract you’re buying actually earns. So let me kill a myth I keep hearing — that pharmacies don’t make money any more. That’s the lie. Of course pharmacies make money. If they genuinely didn’t, why is anyone still set up? Sell your shops and go.

Here’s the honest version: the margin isn’t what it used to be — that much is true. But thinner margins are a reason to run the business properly, not proof the money has gone. Get the fundamentals right and it still pays: your dispensing has to be efficient, your NHS services on top, your private services there, a decent over-the-counter trade — and, yes, a bit of luck. If you’re turning over 10,000–12,000 items with a reasonable counter trade, of course you’re making money.

Ultimately it’s just a shop with a service contract attached. Keep doing the same thing and you’ll get the same result; manage it properly, stay on top of the model and bring new ideas, and it works. It’s tough — but it can absolutely be done. I made a short video on exactly this:

Where the cheap contracts actually are

The cheap contracts are almost never the shiny, high-turnover shops with a polished consultation room and a queue out the door. Those are priced to perfection and everyone’s chasing them. The cheap contracts are the unloved ones — and the reason they’re cheap has nothing to do with the contract and everything to do with the seller.

Owners retire and have nobody to hand to. Owners get ill. Owners burn out — and after a few years of the funding squeeze, plenty have. Some are simply exhausted by the bureaucracy and want their weekends back. When a seller is motivated rather than opportunistic, the price stops being about maximising value and starts being about getting out cleanly. That’s where you find pharmacies changing hands for little over the value of the stock — occasionally for near-nominal sums plus stock at valuation — because the alternative for the seller is closing the doors and getting nothing.

None of this is predatory, and I want to be clear about that. A motivated seller with no succession plan and a tired body is often better off handing a live contract and their staff to someone who’ll actually run it than letting it die. You solve their problem; they hand you an asset. That’s the deal. Your job is to find those situations before the brokers dress them up — which means talking to tired owners, not just scrolling listings.

Structure the deal so barely any of your cash leaves the room

This is the part that separates people who talk about building a group from people who actually do it. When you’re buying an income-producing asset from a motivated seller, the price is only half the negotiation. The other half is how and when you pay — and that’s where you protect your £200k.

• Seller financing / vendor loans. The seller effectively lends you part of the price and you pay it back over time — often out of the very profits the business generates once you’ve fixed it.
• Deferred consideration. A chunk of the price is paid months or years later, not on completion, so your day-one cash requirement drops sharply.
• Earn-outs. Part of what the seller receives is contingent on the business hitting agreed numbers — which aligns them with you and means you’re paying out of results, not hope.
• Staged payments. Break the consideration into tranches tied to milestones rather than one lump on completion.

Stack these and the cash you actually need on day one collapses. The point isn’t to pay less overall — often you pay a fair full price — it’s to pay it out of the business’s own future cash flow rather than out of your pocket up front. That’s what lets a single £200k pot act as the deposit-and-working-capital layer across several deals at once instead of being swallowed whole by one.

Leverage: how £200k controls a multiple of itself

Because the NHS contract is such good security, high-street banks and specialist pharmacy lenders will lend against it — frequently the majority of a pharmacy’s value. That’s the mechanism that turns a modest equity cheque into control of a much larger asset base: your cash is the deposit and the lender funds the rest, secured on the contract’s income. Do that across several sensibly-chosen deals and £200k of equity can sit underneath a group worth many times that.

I’m not going to dress leverage up as free money, because it isn’t. Leverage cuts both ways. The debt has to be serviced every single month whether the branch has a good month or a dreadful one. You’ll almost always sign personal guarantees, which means your own assets — potentially your home — stand behind the borrowing. And the same gearing that magnifies your returns on the way up magnifies your losses on the way down. Leverage is a tool, and like any tool it rewards the careful and punishes the reckless. Borrow against contracts you genuinely understand, at a level you could still service if things got tight.

Bring the expertise, let someone else bring the cash

Here’s a route people forget: you don’t have to fund the equity yourself at all. You have two things an investor doesn’t — the operating expertise to actually run pharmacies and, as a pharmacist, the regulatory standing to be the responsible professional behind them. That’s worth real equity.

In a sweat-equity partnership, an investor puts in the capital and you put in yourself: sourcing the deals, running the sites, keeping them compliant and profitable. In exchange you take a genuine equity stake across several pharmacies for running them well. It’s the same instinct as the “entrepreneur” owner I describe in should you buy a community pharmacy — except here you’re trading your ability across other people’s capital instead of your own. Done honestly, with a clear agreement and aligned incentives, it’s one of the most realistic ways to end up with meaningful ownership of a group without personally funding every shop.

Asset-light first: control the P&L before you own it

If even that feels like a leap, start one rung lower and go asset-light. Become the operator or manager of pharmacies you don’t own — running someone else’s sites under a management arrangement, taking responsibility for the P&L, proving you can turn a tired branch around. You build a track record, a reputation and relationships with owners who’d rather someone competent ran their shop than sell it in a hurry.

Then you convert. The owner who’s watched you rescue their branch is exactly the person who’ll offer you equity, or sell to you on seller-financed terms, when they’re ready to step back. You build the chain by controlling P&Ls before you own them — managing your way into ownership rather than buying your way in. It’s slower, but it costs almost nothing up front and it de-risks everything that comes after, because by the time you own a site you already know exactly how it runs.

Make thin contracts work by attacking the cost base

A single unloved contract might be marginal on its own. The multi-site version of the game is to make a collection of marginal contracts profitable together, by doing at scale what a lone owner can’t. This is the group version of the argument I make in how a pharmacy actually makes money and in the mistakes that cost owners hundreds of thousands.

• Share staff and relief across sites. One relief pharmacist, one skilled dispensing team, flexed across branches instead of each site carrying its own slack.
• Centralise the admin and, where it fits, hub-and-spoke the dispensing. Do the paperwork and the assembly once, efficiently, rather than duplicating it in every shop.
• Relocate and consolidate where the rules allow. Two struggling contracts near each other can sometimes become one viable, better-located site.
• Layer private services on the NHS base. Weight loss, ADHD, private prescribing and online prescribing stacked across every branch turns a thin NHS floor into a real business — just do the private side properly, with the governance that keeps you out of trouble.

Buy a shop outright vs control the contract

Now the honest other side — because this is hustle, not magic

Everything above is real, and people genuinely build groups this way. But I’d be doing you a disservice if I sold it as a passive wealth machine. It’s leverage and graft, and every one of these dangers gets bigger the more sites you add:

• The NHS cash-flow lag, multiplied. You dispense now and get paid roughly a couple of months later. That timing gap is survivable for one shop; across a group it’s a working-capital monster that can strangle a business which looks profitable on paper. This is the number-one killer — respect it.
• Low average item value bites at scale. The margin per prescription is thin. Multiply thin margins by lots of sites and you need real volume and a tight cost base before the group actually makes money.
• TUPE follows every deal. Buy a contract and you generally inherit the staff and their existing rights, at every site. You can’t just clear the decks — you take people on, with their terms and their history.
• Due-diligence and stock-valuation traps. Cheap deals hide expensive surprises — dilapidations, disputed stock valuations, clawbacks, lease problems, missing paperwork. Cheap on the tin is not cheap in reality until you’ve checked.
• The funding squeeze is real. The settlement has been tight; margins are under pressure. You’re building on ground that’s moving, so build in headroom.
• Invoice discounting has a cost and a catch. The firm keeps a drawdown or hold-back and charges a set percentage — read those terms and conditions properly, because they eat into every advance. And the guaranteed NHS income that makes your statement lendable is precisely what you’re mortgaging: discount it to fund the next deposit and you’ve pledged tomorrow’s cash flow, with the personal exposure that comes with it, to grow today.
• Personal guarantees. Leverage across several sites usually means your own assets stand behind the debt. If it goes wrong, it doesn’t politely stay inside the company.
• You have to actually run them. A group is only as good as its operators. Either you can genuinely run several pharmacies at once, or you install managers you truly trust — and finding and keeping those people is its own hard job.

And one myth to kill outright: the old easy routes in — 100-hour contracts, distance-selling loopholes — are largely closed. You are not going to conjure a stack of brand-new contracts out of nowhere. This strategy is almost entirely about acquiring existing contracts cleverly, and market entry is still tightly controlled through the pharmaceutical needs assessment and the 2013 regulations. If you haven’t read why you can’t just open a pharmacy, read it before you get excited — it’s the guardrail on this whole plan.

So, can you build a chain on under £200k?

Not by buying it. £200k doesn’t buy you a chain — it barely deposits one shop. But £200k of your own money, used as equity and spread intelligently across several motivated-seller deals, financed by lenders who back the NHS contract and by sellers happy to be paid out of future profit, and topped up with partners’ capital where you bring the expertise — that can assemble and control a small group. The money is the seed. The real capital is understanding that the contract is the asset, and the willingness to do the unglamorous work of finding tired sellers, structuring clever deals and actually running the shops afterwards.

If you want to know what an owner realistically takes out of all this once it’s built, I’ve written the frank version in how much a pharmacy owner actually makes. And if you want someone who’s built and run these structures to look at your specific plan before you sign anything — or just to tell you honestly whether a deal is as good as it looks — that’s exactly what I do.

Work with me

Frequently asked questions